A Double-Blind, Placebo Controlled Trial of Intravenous Immunoglobulin Therapy in Patient With Small Fiber Neuropathy Associated With Autoantibodies to TS-HDS and FGFR3
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2018
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Peripheral neuropathies
- Focus Therapeutic Use
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 17 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.
- 02 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.